[Use of botulinum neurotoxin therapy]
- PMID: 21747148
[Use of botulinum neurotoxin therapy]
Abstract
Botulinum neurotoxins (BoNTs), produced by the gram-positive anaerobic bacterium Clostridium botulinum, act on motor nerve endings and induce muscle relaxation. BoNT type A and B are used as therapeutic agents. Several preparations of BoNT type A are commercially available; Botox®, Dysport®, and Xeomin® are popular. They differ in the manufacturing method used, for example, BoNT consists of neurotoxin and a complex protein, Botox® and Dysport® contain a complex protein, whereas Xeomin® is free from the protein. However, when applied clinically, there is no significant difference in the efficacy and adverse effects between these BoNT products. Intramuscular BoNT injection is widely recognized as a safe and effective treatment for blepharospasm, hemifacial spasm, cervical dystonia, spasticity, squint, migraine, hyperhidrosis, wrinkles (cosmetic purpose), achalasia, hyperactive bladder, etc. BoNT preparations are used in more than 70 countries. In Japan, BoNT is used to treat blepharospasm, hemifacial spasm, cervical dystonia, and spasticity in addition to being used to treat wrinkles. However, its use is not yet widespread in Japan. This article reviews the structure and characteristics of BoNT, and throws light upon the technique of injecting BoNT.
Similar articles
-
[Use of botulinum neurotoxin for spasticity].Brain Nerve. 2008 Dec;60(12):1421-6. Brain Nerve. 2008. PMID: 19110753 Review. Japanese.
-
Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.Drugs R D. 2010;10(2):67-73. doi: 10.2165/11584780-000000000-00000. Drugs R D. 2010. PMID: 20698714 Free PMC article.
-
[Clinical application of botulinum toxin].Brain Nerve. 2011 Jul;63(7):785-94. Brain Nerve. 2011. PMID: 21747149 Review. Japanese.
-
Routine use of Xeomin in patients previously treated with Botox: long term results.Eur J Neurol. 2009 Dec;16 Suppl 2:2-5. doi: 10.1111/j.1468-1331.2009.02877.x. Eur J Neurol. 2009. PMID: 20002739 Clinical Trial.
-
Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.Clin Neuropharmacol. 2013 Jul-Aug;36(4):122-7. doi: 10.1097/WNF.0b013e318296e630. Clin Neuropharmacol. 2013. PMID: 23783005
Cited by
-
Visual evoked potential changes following Botox administration in patients with blepharospasm.Int Ophthalmol. 2023 Jun;43(6):2101-2107. doi: 10.1007/s10792-023-02639-9. Epub 2023 Jan 18. Int Ophthalmol. 2023. PMID: 36652021
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical